Developing oral and inhaled medicines for chronic lung disease.
Pulmagen’s clinical and preclinical pipeline of therapies for chronic respiratory diseases such as COPD, asthma and cystic fibrosis delivers both symptomatic relief (bronchodilators) and a disease modifying effect (anti-inflammatory).
Industry
Biotech
Status
Realised
Location
UK